IN2014MN01548A - - Google Patents
Info
- Publication number
- IN2014MN01548A IN2014MN01548A IN1548MUN2014A IN2014MN01548A IN 2014MN01548 A IN2014MN01548 A IN 2014MN01548A IN 1548MUN2014 A IN1548MUN2014 A IN 1548MUN2014A IN 2014MN01548 A IN2014MN01548 A IN 2014MN01548A
- Authority
- IN
- India
- Prior art keywords
- compounds
- disclosed
- methods
- agents
- host
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1548MUN2014 IN2014MN01548A (cs) | 2012-02-10 | 2013-02-09 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN147KO2012 | 2012-02-10 | ||
IN1017KO2012 | 2012-09-04 | ||
IN1548MUN2014 IN2014MN01548A (cs) | 2012-02-10 | 2013-02-09 | |
PCT/IB2013/051077 WO2013118102A1 (en) | 2012-02-10 | 2013-02-09 | Antiviral compounds with a heterotricycle moiety |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01548A true IN2014MN01548A (cs) | 2015-05-08 |
Family
ID=54259033
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1547MUN2014 IN2014MN01547A (cs) | 2012-02-10 | 2013-02-08 | |
IN1548MUN2014 IN2014MN01548A (cs) | 2012-02-10 | 2013-02-09 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1547MUN2014 IN2014MN01547A (cs) | 2012-02-10 | 2013-02-08 |
Country Status (14)
Country | Link |
---|---|
US (2) | US9073943B2 (cs) |
EP (2) | EP2812326A1 (cs) |
JP (1) | JP6034883B2 (cs) |
KR (1) | KR20140129034A (cs) |
CN (1) | CN104136433B (cs) |
AU (2) | AU2013217224B2 (cs) |
BR (1) | BR112014019584A8 (cs) |
CA (2) | CA2862755A1 (cs) |
IN (2) | IN2014MN01547A (cs) |
MX (1) | MX2014009546A (cs) |
NZ (2) | NZ628515A (cs) |
SG (2) | SG11201404475TA (cs) |
WO (2) | WO2013118097A1 (cs) |
ZA (1) | ZA201405490B (cs) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9303061B2 (en) | 2011-07-09 | 2016-04-05 | Sunshine Luke Pharma Co., Ltd. | Spiro compounds as Hepatitis C virus inhibitors |
NZ628515A (en) | 2012-02-10 | 2016-06-24 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
WO2015096674A1 (zh) * | 2013-12-23 | 2015-07-02 | 南京圣和药业股份有限公司 | 丙型肝炎病毒抑制剂及其应用 |
WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
KR102794564B1 (ko) * | 2016-04-08 | 2025-04-15 | 듀폰스페셜티머터리얼스코리아 유한회사 | 유기 전계 발광 화합물 및 이를 포함하는 유기 전계 발광 소자 |
EP3889237B1 (en) | 2016-04-15 | 2022-12-28 | Beckman Coulter, Inc. | Photoactive macromolecules and uses thereof |
EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
UY38705A (es) * | 2019-05-23 | 2020-12-31 | Irbm S P A | Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b |
CN114605310B (zh) * | 2022-04-09 | 2024-05-07 | 都创(上海)医药科技股份有限公司 | 一种氮杂五元环并三元环羧酸酯衍生物及其盐的合成方法 |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
AU2003261434A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
US7384974B2 (en) | 2003-07-31 | 2008-06-10 | Taisha Pharmaceutical Co., Ltd. | 4,5-dihydronaphtho[1,2-b]thiophene derivative |
ES2349143T3 (es) | 2003-09-19 | 2010-12-28 | Janssen Pharmaceutica Nv | Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos. |
AU2004287573A1 (en) | 2003-11-07 | 2005-05-19 | F. Hoffmann-La Roche Ag | Benzo [b][1,4] dioxepine derivatives |
GB0421908D0 (en) | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
GB0501964D0 (en) | 2005-01-31 | 2005-03-09 | Arrow Therapeutics Ltd | Chemical compounds |
US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
HRP20100542T1 (hr) | 2005-09-16 | 2010-11-30 | Arrow Therapeutics Limited | Derivati bifenila i njihova uporaba za liječenje hepatitisa c |
US7595398B2 (en) | 2005-12-12 | 2009-09-29 | Smithkline Beecham Corporation | N-(5-membered aromatic ring)-amido anti-viral compounds |
CA2633541A1 (en) | 2005-12-12 | 2007-06-21 | Genelabs Technologies, Inc. | N-(6-membered aromatic ring)-amido anti-viral compounds |
WO2007082554A1 (en) | 2006-01-23 | 2007-07-26 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Modulators of hcv replication |
US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008048589A2 (en) | 2006-10-13 | 2008-04-24 | Xtl Biopharmaceuticals Ltd | Compounds and methods for treatment of hcv |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2097405A2 (en) | 2006-11-21 | 2009-09-09 | Smithkline Beecham Corporation | Anti-viral compounds |
EP2099778A2 (en) | 2006-11-21 | 2009-09-16 | Smithkline Beecham Corporation | Amido anti-viral compounds |
US7521444B2 (en) | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008154601A1 (en) | 2007-06-12 | 2008-12-18 | Genelabs Technologies, Inc. | Anti-viral inhibitors and methods of use |
CA2691444C (en) | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
WO2009034390A1 (en) | 2007-09-14 | 2009-03-19 | Arrow Therapeutics Limited | Heterocyclic derivatives and their use in treating hepatitis c |
EP2205584A1 (en) | 2007-10-10 | 2010-07-14 | Novartis Ag | Spiropyrrolidines and their use against hcv and hiv infection |
CN102015692A (zh) | 2008-02-12 | 2011-04-13 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
CN101998952B (zh) | 2008-02-12 | 2014-10-08 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
KR101492672B1 (ko) | 2008-02-13 | 2015-02-16 | 브리스톨-마이어스 스큅 컴퍼니 | C형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸 |
PT2280973E (pt) | 2008-04-23 | 2013-02-04 | Gilead Sciences Inc | Análogos de carba-nucleósido para tratamento antiviral |
US8133884B2 (en) | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
WO2010039195A2 (en) | 2008-09-23 | 2010-04-08 | The Board Of Trustees Of The Leland Stanford Junior University | Screening for inhibitors of hcv amphipathic helix (ah) function |
CA2750577A1 (en) * | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
KR101724759B1 (ko) | 2009-02-10 | 2017-04-07 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 카르바-뉴클레오시드 유사체 |
US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
WO2010096462A1 (en) | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
EP2398474A4 (en) | 2009-02-23 | 2012-12-05 | Presidio Pharmaceuticals Inc | HCV NS5A SHEMMER |
US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US9150554B2 (en) | 2009-03-27 | 2015-10-06 | Presidio Pharmaceuticals, Inc. | Fused ring inhibitors of hepatitis C |
US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
CN103880862B (zh) | 2009-03-27 | 2018-09-25 | 默沙东公司 | 丙型肝炎病毒复制的抑制剂 |
US20110237636A1 (en) | 2009-03-30 | 2011-09-29 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8088368B2 (en) | 2009-05-13 | 2012-01-03 | Gilead Sciences, Inc. | Antiviral compounds |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
CN102471323A (zh) | 2009-08-07 | 2012-05-23 | 泰博特克药品公司 | 苯基乙炔基衍生物作为丙型肝炎病毒抑制剂 |
WO2011031934A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
WO2011081918A1 (en) | 2009-12-14 | 2011-07-07 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2011087740A1 (en) | 2009-12-22 | 2011-07-21 | Schering Corporation | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
JP2013515746A (ja) | 2009-12-24 | 2013-05-09 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症の治療又は予防のための類似体 |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
WO2011106929A1 (en) | 2010-03-02 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus ns5b polymerase |
TW201136919A (en) | 2010-03-02 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | Inhibitors of hepatitis C virus NS5B polymerase |
JP2013521279A (ja) | 2010-03-04 | 2013-06-10 | エナンタ ファーマシューティカルズ インコーポレイテッド | Hcv複製の阻害剤としての医薬併用剤 |
KR20130008040A (ko) | 2010-03-09 | 2013-01-21 | 머크 샤프 앤드 돔 코포레이션 | 융합된 트리시클릭 실릴 화합물 및 바이러스성 질환의 치료를 위한 그의 사용 방법 |
WO2011127350A1 (en) | 2010-04-09 | 2011-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
WO2011151652A1 (en) | 2010-06-03 | 2011-12-08 | Arrow Therapeutics Limited | Benzodiazepine compounds useful for the treatment of hepatitis c |
WO2011151651A1 (en) | 2010-06-03 | 2011-12-08 | Arrow Therapeutics Limited | Benzodiazepine compounds useful for the treatment of hepatitis c |
EP2575819A4 (en) | 2010-06-04 | 2013-11-27 | Enanta Pharm Inc | INHIBITORS OF HEPATITIS C VIRUS |
EP2580209A4 (en) | 2010-06-09 | 2013-11-06 | Presidio Pharmaceuticals Inc | INHIBITORS OF HCV NS5A PROTEIN |
EP2598149A4 (en) | 2010-07-26 | 2014-09-10 | Merck Sharp & Dohme | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES |
MX337936B (es) | 2010-08-04 | 2016-03-29 | Bristol Myers Squibb Co | Compuestos inhibidores del virus de la hepatitis c. |
US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
WO2012021704A1 (en) | 2010-08-12 | 2012-02-16 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
MX2013001869A (es) | 2010-08-17 | 2013-06-28 | Vertex Pharma | Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae. |
EP2619195A1 (en) | 2010-09-24 | 2013-07-31 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
KR20140001879A (ko) | 2010-09-29 | 2014-01-07 | 머크 샤프 앤드 돔 코포레이션 | C형 간염 바이러스 감염을 치료하기 위한 테트라시클릭 인돌 유도체 |
EP2621932A4 (en) | 2010-09-29 | 2014-03-26 | Merck Sharp & Dohme | TETRACYCLIC HETEROCYCLUS COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS |
CA2817840A1 (en) | 2010-11-17 | 2012-05-24 | Gilead Sciences, Inc. | Antiviral compounds |
NZ628515A (en) | 2012-02-10 | 2016-06-24 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
-
2013
- 2013-02-08 NZ NZ628515A patent/NZ628515A/en not_active IP Right Cessation
- 2013-02-08 IN IN1547MUN2014 patent/IN2014MN01547A/en unknown
- 2013-02-08 SG SG11201404475TA patent/SG11201404475TA/en unknown
- 2013-02-08 CA CA2862755A patent/CA2862755A1/en not_active Abandoned
- 2013-02-08 AU AU2013217224A patent/AU2013217224B2/en not_active Expired - Fee Related
- 2013-02-08 EP EP13715002.5A patent/EP2812326A1/en not_active Ceased
- 2013-02-08 WO PCT/IB2013/051062 patent/WO2013118097A1/en active Application Filing
- 2013-02-08 US US14/375,534 patent/US9073943B2/en not_active Expired - Fee Related
- 2013-02-09 NZ NZ628445A patent/NZ628445A/en not_active IP Right Cessation
- 2013-02-09 EP EP13708912.4A patent/EP2812327A1/en not_active Withdrawn
- 2013-02-09 KR KR20147023151A patent/KR20140129034A/ko not_active Withdrawn
- 2013-02-09 US US14/375,530 patent/US9073942B2/en not_active Expired - Fee Related
- 2013-02-09 WO PCT/IB2013/051077 patent/WO2013118102A1/en active Application Filing
- 2013-02-09 AU AU2013217229A patent/AU2013217229B2/en not_active Expired - Fee Related
- 2013-02-09 CA CA2862330A patent/CA2862330A1/en not_active Abandoned
- 2013-02-09 CN CN201380008883.4A patent/CN104136433B/zh not_active Expired - Fee Related
- 2013-02-09 MX MX2014009546A patent/MX2014009546A/es unknown
- 2013-02-09 JP JP2014556185A patent/JP6034883B2/ja not_active Expired - Fee Related
- 2013-02-09 BR BR112014019584A patent/BR112014019584A8/pt active Search and Examination
- 2013-02-09 IN IN1548MUN2014 patent/IN2014MN01548A/en unknown
- 2013-02-09 SG SG11201404365SA patent/SG11201404365SA/en unknown
-
2014
- 2014-07-25 ZA ZA2014/05490A patent/ZA201405490B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2013217229B2 (en) | 2017-03-02 |
AU2013217224A1 (en) | 2014-08-21 |
WO2013118102A1 (en) | 2013-08-15 |
EP2812327A1 (en) | 2014-12-17 |
SG11201404475TA (en) | 2014-08-28 |
US20150010505A1 (en) | 2015-01-08 |
CA2862755A1 (en) | 2013-08-15 |
NZ628515A (en) | 2016-06-24 |
US20150010504A1 (en) | 2015-01-08 |
IN2014MN01547A (cs) | 2015-05-08 |
JP2015510512A (ja) | 2015-04-09 |
US9073942B2 (en) | 2015-07-07 |
SG11201404365SA (en) | 2014-10-30 |
BR112014019584A2 (cs) | 2017-06-20 |
ZA201405490B (en) | 2015-10-28 |
BR112014019584A8 (pt) | 2017-07-11 |
EP2812326A1 (en) | 2014-12-17 |
MX2014009546A (es) | 2015-10-29 |
KR20140129034A (ko) | 2014-11-06 |
CN104136433A (zh) | 2014-11-05 |
CA2862330A1 (en) | 2013-08-15 |
US9073943B2 (en) | 2015-07-07 |
AU2013217229A1 (en) | 2014-08-21 |
AU2013217224B2 (en) | 2017-04-06 |
JP6034883B2 (ja) | 2016-11-30 |
NZ628445A (en) | 2016-05-27 |
CN104136433B (zh) | 2016-05-04 |
WO2013118097A1 (en) | 2013-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01548A (cs) | ||
PH12014502739A1 (en) | Macrocyclic inhibitors of flaviviridae viruses | |
NZ703040A (en) | Macrocyclic inhibitors of flaviviridae viruses | |
NZ703066A (en) | Macrocyclic inhibitors of flaviviridae viruses | |
NZ703064A (en) | Inhibitors of hepatitis c virus | |
MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
MX2012008211A (es) | Inhibidores de virus flaviviridae. | |
MX2013006475A (es) | Inhibidores macrociclicos de virus flaviviridae. | |
EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
MX2022013596A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
NZ748966A (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
MX2012000959A (es) | Inhibidores de los virus flaviviridae. | |
CL2011002830A1 (es) | Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c. | |
EA201301158A1 (ru) | Противовирусные соединения | |
HK1211290A1 (en) | Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
IN2012DN01855A (cs) | ||
PH12013501543A1 (en) | Hepatitis c virus inhibitors | |
PH12014500385A1 (en) | Benzofuran compounds for the treatment of hepatitis c virus infections | |
WO2014116772A3 (en) | Squaric derivatives for the treatment of hepatitis c | |
IN2011CH03893A (cs) | ||
HK1198387A1 (zh) | 用作黃病毒科病毒抑制物之噻吩-2-羧酸衍生物 | |
TN2013000335A1 (en) | Hepatitis c virus inhibitors |